EUVIMEDEUVIMED entdecken
Open Access

Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis

Shaojian Lin iD, Liangbo Wang, Changxi Han, Yuting Dai, Changsheng Li, Yanting Liu, Bo Zhang, Ning Huang, Anke Zhang, Tao Zhang, Yu Wang, Jing Xie und 6 weitere

Neuro-Oncology · 04.11.2024 · 26 (11) · 2010-2026

DOI: 10.1093/neuonc/noae130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.07.2024. Verfasst von Shaojian Lin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Pituitary Neoplasms, STAT3 Transcription Factor, Cabergoline, Receptor, Serotonin, 5-HT2B. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Research Center for Translational Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Managing nonfunctioning pituitary adenomas (NFPAs) is difficult due to limited drug treatments. Cabergoline’s (CAB) effectiveness for NFPAs is debated. This study explores the role of HTR2B in NFPAs and its therapeutic potential.

Methods

We conducted screening of bulk RNA-sequencing data to analyze HTR2B expression levels in NFPA samples. In vitro and in vivo experiments were performed to evaluate the effects of HTR2B modulation on tumor growth and cell cycle regulation. Mechanistic insights into the HTR2B-mediated signaling pathway were elucidated using pharmacological inhibitors and molecular interaction assays.

Results

Elevated HTR2B expression was detected in NFPA samples, which was associated with increased tumor survival. Inhibition of HTR2B activity resulted in the suppression of tumor growth through modulation of the G2M cell cycle. The inhibition of HTR2B with PRX-08066 was found to block STAT3 phosphorylation and nuclear translocation by interfering with the Gαq/PLC/PKC pathway. A direct interaction between PKC-γ and STAT3 was critical for STAT3 activation. CAB was shown to activate pSTAT3 via HTR2B, reducing its therapeutic potential. However, the combination of an HTR2B antagonist with CAB significantly inhibited tumor cell proliferation in HTR2B-expressing pituitary tumor cell lines, a xenografted pituitary tumor model, and patient-derived samples. Analysis of patient-derived data indicated that a distinct molecular pattern characterized by upregulated HTR2B/PKC-γ and downregulated BTG2/GADD45A may benefit from combination treatment with CAB and PRX-08066.

Conclusions

HTR2B is a potential therapeutic target for NFPAs, and its inhibition could improve CAB efficacy. A dual therapy approach may be beneficial for NFPA patients with high HTR2B expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsSTAT3 Transcription FactorCabergolineReceptor, Serotonin, 5-HT2BXenograft Model Antitumor AssaysCell ProliferationAdenomaHumansAnimalsMiceMice, NudeSignal TransductionProtein Kinase CTumor Cells, CulturedGene Expression Regulation, NeoplasticCell Line, TumorApoptosisMale

Stichwörter der Autor:innen

Gαq/PLC/PKC-γHTR2BSTAT3cabergolinepituitary adenomas

Substanzen

STAT3 Transcription FactorCabergolineSTAT3 protein, humanReceptor, Serotonin, 5-HT2Bprotein kinase C gammaProtein Kinase C

Autor:innen und Institutionen

  • Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
  • Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Shaojian Lin, Zhe Bao Wu

Förderung

  • National Natural Science Foundation of China
  • National Research Center for Translational Medicine

Zitieren

APA

Lin, S., Wang, L., Han, C., Dai, Y., Li, C., Liu, Y., Zhang, B., Huang, N., Zhang, A., Zhang, T., Wang, Y., Xie, J., Tang, H., Cheng, Y., Yao, H., Lou, M., Xue, L., & Wu, Z. B. (2024). Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis. Neuro-Oncology, 26(11), 2010-2026. https://doi.org/10.1093/neuonc/noae130

Vancouver

Lin S, Wang L, Han C, Dai Y, Li C, Liu Y, et al. Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis. Neuro-Oncology. 2024;26(11):2010-2026. doi:10.1093/neuonc/noae130

BibTeX
@article{Lin2024,
  author = {Lin, Shaojian and Wang, Liangbo and Han, Changxi and Dai, Yuting and Li, Changsheng and Liu, Yanting and Zhang, Bo and Huang, Ning and Zhang, Anke and Zhang, Tao and Wang, Yu and Xie, Jing and Tang, Hao and Cheng, Yijun and Yao, Hong and Lou, Meiqing and Xue, Li and Wu, Zhe Bao},
  title = {Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKC γ /STAT3 axis},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {2010--2026},
  doi = {10.1093/neuonc/noae130}
}
Kostenlos starten →